Fibrogen INC 8-K filings

Kyntra Bio, Inc. has received the final $4 million holdback payment from AstraZeneca, concluding the sale of its China operations.

Kyntra Bio reported Q1 2026 financial results, highlighting progress in its FG-3246 and roxadustat programs, alongside a cash runway into 2028.

Kyntra Bio, Inc. received a notice from Nasdaq indicating it no longer meets continued listing requirements due to insufficient total assets and revenue, and has 45 days to submit a compliance plan.

Kyntra Bio announced its fourth quarter and full year 2025 financial results, highlighting progress in its FG-3246 and roxadustat clinical programs and a cash runway into 2028.

FibroGen rebrands as Kyntra Bio, shifting strategic focus to oncology and rare disease assets with a new Nasdaq trading symbol KYNB.

FibroGen reported third-quarter 2025 financial results, highlighted by the $220 million sale of its China operations to AstraZeneca, extending its cash runway into 2028.

FibroGen, Inc. announced it received a $6.4 million payment from AstraZeneca, fully satisfying the first holdback from the sale of its China operations.

FibroGen, Inc. announced the completion of the sale of its FibroGen International (Hong Kong) Ltd. subsidiary to AstraZeneca Treasury Limited for approximately $220 million, using proceeds to repay debt.

FibroGen completed the sale of its China subsidiary to AstraZeneca for approximately $220 million, significantly strengthening its financial position and extending its cash runway into 2028.

FibroGen, Inc. announced it received China regulatory approval for the sale of its FibroGen China subsidiary to AstraZeneca, with the transaction expected to close in Q3 2025.

FibroGen, Inc. has entered into a fourth amendment to its financing agreement, reducing the required minimum qualified cash balance from $18.75 million to $15 million.

FibroGen reported significantly reduced net losses in Q2 2025, bolstered by an increased sale price for its China operations, extending its cash runway into 2028 and advancing key clinical programs.

FibroGen, Inc. has entered into a third amendment to its financing agreement with Morgan Stanley Tactical Value funds, reducing the minimum required qualified cash balance from $22.5 million to $18.75 million.

FibroGen, Inc. has terminated its 2021 Exclusive License and Option Agreement with HiFiBiO Inc., simultaneously licensing its anti-CCR8 and anti-Gal-9 intellectual property to HiFiBiO in exchange for potential future royalties and revenue shares.

FibroGen, Inc. announced a 1-for-25 reverse stock split, effective June 16, 2025, to increase its share price and meet Nasdaq's minimum bid price requirement for continued listing.

FibroGen, Inc. announced stockholder approval for a reverse stock split to maintain Nasdaq listing, the election of a new director, and a reduction in its minimum required cash balance, alongside a director resignation.

FibroGen announces Q1 2025 financial results, an update on the sale of FibroGen China to AstraZeneca, and progress on its drug development programs.

FibroGen, Inc. has amended its bylaws to reduce the quorum requirement for stockholder meetings to one-third of outstanding shares, effective immediately.

FibroGen's FG-3246 demonstrates encouraging anti-cancer activity and an acceptable safety profile in a Phase 1 study for patients with metastatic castration-resistant prostate cancer, paving the way for a Phase 2 trial.

FibroGen and Fortis Therapeutics have amended their agreements, pushing the option exercise deadline to December 31, 2027.

FibroGen reports the sale of its China operations to AstraZeneca for approximately $160 million and provides financial results for Q4 and full year 2024, highlighting a cost reduction plan and a focus on its ADC program.

FibroGen has entered into an agreement with BofA Securities to sell up to $30 million of its common stock through an at-the-market offering.

FibroGen is selling its China subsidiary to AstraZeneca for approximately $160 million, which includes $85 million for the enterprise value and an estimated $75 million in net cash held in China, extending the company's cash runway into 2027.

FibroGen has announced the appointment of David DeLucia as its new Chief Financial Officer, effective December 16, 2024.

FibroGen announced a 15% year-over-year revenue increase in the third quarter of 2024, primarily due to strong sales of roxadustat in China, while also providing updates on its clinical programs and cost reduction efforts.

FibroGen, Inc. has terminated its lease agreement for its San Francisco premises to reduce operating expenses and preserve cash, agreeing to a $10 million settlement with its landlord.

FibroGen has received a notification from Nasdaq that its stock price has fallen below the minimum $1.00 threshold for continued listing, triggering a potential delisting process.

FibroGen, Inc. reports the resignation of three board members effective September 30, 2024, leading to new committee assignments.

FibroGen, Inc. has announced the departure of its Chief Financial Officer and Chief Medical Officer as part of an ongoing cost reduction plan.

FibroGen is implementing a restructuring plan, including a 75% reduction in its U.S. workforce, following negative clinical trial results for pamrevlumab.